G-CSF, rt-PA and combination therapy after experimental thromboembolic stroke.
BACKGROUND
Granulocyte Colony-Stimulating Factor (G-CSF) has remarkable neuroprotective properties. Due to its proven safety profile, G-CSF is currently used in clinical stroke trials. As neuroprotectants are considered to be more effective in the early phase of cerebral ischemia and during reperfusion, G-CSF should to be tested in combination with thrombolysis. Therefore, combination therapy was investigated in an experimental model of thromboembolic stroke.


METHODS
Male Wistar rats (n = 72) were subjected to a model of thromboembolic occlusion (TE) of the middle cerebral artery. Different groups (n = 12 each) treated by recombinant tissue-plasminogen activator (rt-PA) or/and G-CSF: group control (control), group early G-CSF (G-CSF 60 min after TE), group rt-PA (rt-PA 60 min after TE), group com (combination rt-PA/G-CSF), group delayed rt-PA (rt-PA after 180 min), group deco (G-CSF after 60 min, rt-PA after 180 min). Animals were investigated by magnetic resonance imaging (MRI) and silver infarct staining (SIS) 24 hours after TE.


RESULTS
Early G-CSF or rt-PA reduced the infarct size compared to all groups (p < 0.05 to p < 0.01) with the exception of group com, (p = n.s.) as measured by T2, DWI, and SIS. Late administration of rt-PA lead to high mortality and larger infarcts compared to all other groups (p < 0.05 to p < 0.01). Pre-treatment by G-CSF (deco) reduced infarct site compared to delayed rt-PA treatment (p < 0.05). G-CSF did not significantly influence PWI when combined with rt-PA. All animals treated by rt-PA showed improved parameters in PWI indicating reperfusion.


CONCLUSIONS
G-CSF was neuroprotective when given early after TE. Early combination with rt-PA showed no additional benefit compared to rt-PA or G-CSF alone, but did not lead to side effects. Pretreatment by G-CSF was able to reduce deleterious effects of late rt-PA treatment.
Kollmar
Rainer
R
Department of Neurology, University of Erlangen, Erlangen, Germany. rainer.kollmar@uk-erlangen.de
Henninger
Nils
N
Urbanek
Christian
C
Schwab
Stefan
S
J Cereb Blood Flow Metab. 2000 Mar;20(3):452-7
10724108
Stroke. 2009 Dec;40(12):e647-56
19834012
Cell Cycle. 2005 Dec;4(12):1753-7
16258290
Neurosci Lett. 1999 Oct 22;274(2):79-82
10553942
Anesthesiology. 2000 Mar;92(3):754-63
10719954
Rofo. 1999 Jul;171(1):3-14
10464498
Circulation. 2004 Sep 28;110(13):1847-54
15381647
Neurosurgery. 1992 Jul;31(1):100-6; discussion 106-7
1641086
Thromb Haemost. 1981 Aug 28;46(2):561-5
6795744
Stroke. 2003 Mar;34(3):745-51
12624302
Eur J Pharmacol. 2003 Jan 5;458(3):327-8
12504790
BMC Biol. 2006 Oct 18;4:36
17049076
Circulation. 2006 Feb 7;113(5):701-10
16461843
N Engl J Med. 2008 Sep 25;359(13):1317-29
18815396
Neuroscience. 2006 Dec 28;143(4):965-74
17084035
Lancet. 2004 Mar 6;363(9411):768-74
15016487
Stroke. 1999 May;30(5):1134-41
10229755
J Clin Invest. 2005 Aug;115(8):2083-98
16007267
J Magn Reson Imaging. 1997 Nov-Dec;7(6):1109-15
9400856
J Cereb Blood Flow Metab. 2005 Apr;25(4):431-9
15660101
CMAJ. 2006 Mar 28;174(7):927-33
16517764
J Cereb Blood Flow Metab. 1997 Oct;17(10):1048-56
9346429
Exp Neurol. 2004 Nov;190(1):204-12
15473993
J Cereb Blood Flow Metab. 1990 Mar;10(2):290-3
1689322
Neurosci Lett. 2008 Feb 27;432(3):167-9
18255224
Stroke. 2006 Dec;37(12):2979-83
17082474
J Cereb Blood Flow Metab. 2006 Mar;26(3):402-13
16049425